Fulford (India) Peer Comparison

NSE: FULFORD | BSE: 506803

₹2,362.00

₹1.00 (0.04%)

As on 30-Jul-2015IST

Market cap

₹921 Cr

Revenue (TTM)

₹109 Cr

P/E Ratio

32.5

P/B Ratio

6.1

Div. Yield

0 %

Edit

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	921	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	109	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	28.33	414.00	288.22	-371.81	387.35
Net Margin (%)	23.93	11.23	14.79	-3.93	26.01
RoE (%)	13.36	8.38	29.77	-3.85	25.18
Price to Earnings	32.51	78.49	103.71	--	69.57
Price-To-Book	6.15	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	109.36	2,843.99	263.02	--	239.64
Total Income	118.42	2,904.07	281.09	--	242.49
Total Expenditure	79.28	2,746.23	182.42	--	198.63
EBITDA	30.07	97.76	80.60	--	41.02
Depreciation	0.09	224.14	18.45	--	3.52
EBIT	29.99	-126.38	62.15	--	37.50
Interest	0.29	275.74	6.20	--	5.59
Other Income	9.06	60.08	18.07	--	2.84
Exceptional Items	--	--	--	--	--
Profit before Tax	38.76	-342.04	74.01	--	34.75
Provision for Tax	10.43	-204.09	24.60	--	7.28
Profit after Tax	28.33	-137.95	49.41	--	27.47

Liabilities (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	225.93	2,671.67	340.50	--	111.81
Minority Interest	--	385.79	--	--	--
Non-Current Liabilities	-2.88	1,194.85	9.30	--	25.46
Current Liabilities	26.61	3,497.18	77.54	--	94.61
Total Liabilities	254.91	8,147.66	430.39	--	231.89

Assets (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	78.87	5,319.66	162.50	--	104.93
Current Assets	170.80	2,400.54	264.84	--	121.04
Total Assets	254.91	8,147.66	430.39	--	231.89
Total Debt*	0.00	3,213.23	30.27	--	59.42
Net Current Assets	144.19	-1,096.64	187.31	--	26.42
Contingent Liabilities	143.54	641.08	46.45	--	0.07

Cashflow (₹ Cr)

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	3.65	648.96	5.47	--	27.08
Cash Flow from Investing Activities	69.78	-155.53	-84.34	--	-23.94
Cash from Financing Activities	-0.77	-679.58	80.07	--	0.19
Net Cash Inflow / Outflow	72.66	-186.15	1.21	--	3.33

Ratios

Profitability Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	18.42	-1.11	26.00	--	27.09
ROE (%)	13.36	-5.22	18.67	--	29.78
ROA (%)	12.02	-1.80	13.65	--	12.34
EBIT Margin (%)	35.79	5.55	37.51	--	18.30
Net Margin (%)	23.93	-4.75	17.58	--	11.33
Cash Profit Margin (%)	25.99	3.03	25.80	--	12.93

Growth Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	9.65	-20.24	71.02	--	0.47
EBIT Growth (%)	-2.31	1,004.01	159.60	--	3.29
Net Profit Growth (%)	1.95	55.76	168.16	--	17.92
EPS Growth (%)	1.95	64.44	148.52	--	17.92
Book Value Growth (%)	14.07	-0.03	68.83	--	34.77

Valuation Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	0.00	0.00	--	0.00
Price / Book Value	0.00	0.72	0.00	--	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-3.40	30.78	0.00	--	1.51
Market Cap (₹ Cr)	0.00	1,913.03	0.00	--	0.00

Solvency Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	1.22	0.09	--	0.56
Short term debt to equity ratio	--	0.34	0.06	--	0.30
Current Ratio	6.42	0.69	3.42	--	1.28
Quick Ratio	6.34	0.48	2.93	--	0.73
Interest Coverage	134.58	-0.24	12.93	--	7.22

Operating Efficiency Ratios

	Fulford (India)	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	16.09	43.70	53.26	--	23.54
Asset Turnover	0.46	0.37	0.73	--	1.08
Receivable days	34.64	161.49	155.79	--	100.90
Inventory Days	23.56	98.54	39.61	--	69.31
Payable days	176.33	263.19	159.03	--	169.65
Cash Conversion Cycle	-118.13	-3.16	36.37	--	0.56